Skip to main content
SpringerLink
Log in

Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in molecularly characterized patients for BRAF and NRAS mutations receiving conventional treatment. We investigated associations between outcomes [competing risk of local and distant brain failure (LF, DF) and overall survival (OS)] and clinical/pathological features of patients with known mutation status following initial treatment of MBM. Competing risk analysis was performed using the methods of Fine and Gray. We identified 235 patients with MBM diagnosed from 2005 to 2011. Mutation prevalence was BRAF non-V600K 98 (42%), BRAF V600K 34 (14%), NRAS 43 (18%), and wild-type for both genes (WT) 60 (26%) patients. Six month cumulative incidence LF rates were 3% for combined SRS or surgery with adjuvant radiation, 18% for surgery, 18% for SRS, 60% for WBRT, and 67% for systemic therapy. On multivariate analysis, only mutation status and initial treatment type were found to be independent predictors of local control. As compared to WT, NRAS (HR 2.58, 95% CI 1.18–5.67, p = 0.02) and BRAF V600K (HR 2.83, 95% CI 1.23–6.47, p = 0.01) mutational status were statistically significant while BRAF non-V600K status was not statistically significant (p = 0.23). Mutation status was not associated with DF or OS. BRAF V600K and NRAS mutation status predict increased LF following conventional treatments for MBM. These data can inform the design and interpretation of future MBM trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu W-J et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687–1696

    Article  PubMed  Google Scholar 

  2. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF et al (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol Off J Am Soc Clin Oncol 22(7):1293–1300

    Article  CAS  Google Scholar 

  3. Raizer JJ, Hwu W-J, Panageas KS, Wilton A, Baldwin DE, Bailey E et al (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro-Oncol 10(2):199–207

    Article  PubMed  PubMed Central  Google Scholar 

  4. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol Off J Am Soc Clin Oncol 30(4):419–425

    Article  Google Scholar 

  5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954

    Article  CAS  PubMed  Google Scholar 

  6. Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28(6):578–588

    Article  CAS  PubMed  Google Scholar 

  7. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol Off J Am Soc Clin Oncol 30(20):2522–2529

    Article  Google Scholar 

  8. Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen C-Y et al (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigm Cell Melanoma Res 24(4):666–672

    Article  CAS  Google Scholar 

  9. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP et al (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 17(2):229–235

    Article  CAS  Google Scholar 

  10. Broekaert SMC, Roy R, Okamoto I, van den Oord J, Bauer J, Garbe C et al (2010) Genetic and morphologic features for melanoma classification. Pigm Cell Melanoma Res 23(6):763–770

    Article  CAS  Google Scholar 

  11. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ et al (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 29(10):1239–1246

    Article  Google Scholar 

  12. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014–4023

    Article  CAS  PubMed  Google Scholar 

  13. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF et al (2012) Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 18(12):3242–3249

    Article  CAS  Google Scholar 

  14. Bucheit AD, Syklawer E, Jakob JA, Bassett RL, Curry JL, Gershenwald JE et al (2013) Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer 119(21):3821–3829

    Article  CAS  PubMed  Google Scholar 

  15. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet Lond Engl 379(9829):1893–1901

    Article  CAS  Google Scholar 

  16. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095

    Article  CAS  PubMed  Google Scholar 

  17. Ascierto PA, Minor D, Ribas A, Lebbe C, O’Hagan A, Arya N et al (2013) Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 31(26):3205–3211

    Article  CAS  Google Scholar 

  18. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet Lond Engl 380(9839):358–365

    Article  CAS  Google Scholar 

  20. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 22(11):2101–2107

    Article  CAS  Google Scholar 

  21. Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA et al (2017) The prognostic value of BRAF, C-KIT, and NRAS mutations in melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys 98(5):1069–1077

    Article  CAS  PubMed  Google Scholar 

  22. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L et al (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer Oxf Engl 1990 50(3):611–621

    CAS  Google Scholar 

  23. Azer MWF, Menzies AM, Haydu LE, Kefford RF, Long GV (2014) Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 120(4):530–536

    Article  CAS  PubMed  Google Scholar 

  24. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509

    Article  Google Scholar 

  25. Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381–387

    Article  CAS  PubMed  Google Scholar 

  26. Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388–1395

    Article  CAS  PubMed  Google Scholar 

  27. Jones HA, Hahn SM, Bernhard E, McKenna WG (2001) Ras inhibitors and radiation therapy. Semin Radiat Oncol 11(4):328–337

    Article  CAS  PubMed  Google Scholar 

  28. Morris SL, Low SH, A’Hern RP, Eisen TG, Gore ME, Nutting CM et al (2004) A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer 91(5):829–833

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Xu Z, Lee C-C, Ramesh A, Mueller AC, Schlesinger D, Cohen-Inbar O et al (2017) BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg 126(3):726–734

    Article  PubMed  Google Scholar 

  30. Kotecha R, Miller JA, Venur VA, Mohammadi AM, Chao ST, Suh JH et al (2017) Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. J Neurosurg 1–10. https://doi.org/10.3171/2017.1.JNS162797

  31. Wolf A, Zia S, Verma R, Pavlick A, Wilson M, Golfinos JG et al (2016) Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol 127(3):607–615

    Article  CAS  PubMed  Google Scholar 

  32. Davies MA, Saiag P, Robert C, Grob J-J, Flaherty KT, Arance A et al (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863–873

    Article  CAS  PubMed  Google Scholar 

  33. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res Off J Am Assoc Cancer Res 9(17):6483–6488

    CAS  Google Scholar 

Download references

Funding

No specific funding was used in the support of this work.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 97, Houston, TX, 77030, USA

    Penny Fang, Nicholas S. Boehling, Eugene J. Koay, Stephen H. Settle, Paul D. Brown & Erik P. Sulman

  2. Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    Amanda D. Bucheit, John A. Jakob & Michael A. Davies

Authors
  1. Penny Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas S. Boehling
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eugene J. Koay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amanda D. Bucheit
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John A. Jakob
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stephen H. Settle
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul D. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael A. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Erik P. Sulman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erik P. Sulman.

Ethics declarations

Conflict of interest

The authors report no conflict of interest.

Additional information

Penny Fang and Nicholas S. Boehling are co-first author.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 17 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fang, P., Boehling, N.S., Koay, E.J. et al. Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. J Neurooncol 137, 67–75 (2018). https://doi.org/10.1007/s11060-017-2695-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2695-2

Keywords

Search

Navigation